Public Watchlist

Bio Tech Plays. Mispricing

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

15+ years as a clinical vet, researcher & founder. I track biotech mispricings for analytical insights.

1.8k Views

Watching

		FV & Narrative	Valuation	Growth	Analyst Target
CAPR Capricor Therapeutics US$9.0884.4% undervalued intrinsic discount 8.4%7D -68.0%3M A US$58author fair value 12 Julauthor updated this narrative The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
MBIO Mustang Bio US$0.5271.0% undervalued intrinsic discount 2.9%7D -19.7%3M A US$1.8author fair value 24 Junauthor updated this narrative A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???
PRTC PureTech Health UK£1.2363.0% undervalued intrinsic discount 2.7%7D -6.7%3M A UK£3.31author fair value 19 Julauthor updated this narrative An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.
TDOC Teladoc Health US$6.3058.0% undervalued intrinsic discount 2.3%7D -21.9%3M A US$15author fair value 21 Julauthor updated this narrative Pandemic Relic or Cash-Flow Bargain?
AMGN Amgen US$385.657.1% overvalued intrinsic discount 2.2%7D 14.2%3M A US$359.98author fair value 19 Julauthor updated this narrative A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.
RARE Ultragenyx Pharmaceutical US$14.5144.2% undervalued intrinsic discount 1.5%7D -47.1%3M A US$26author fair value 19 Julauthor updated this narrative burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.
RCKT Rocket Pharmaceuticals US$3.3866.3% undervalued intrinsic discount 0.7%7D 0.7%3M A US$10author fair value 24 Junauthor updated this narrative The Structural Disconnect Between Market Valuation and Operational Maturity
CSBT.F Kuros Biosciences US$24.0093.0% undervalued intrinsic discount 0%7D n/a3M A US$342.18author fair value 26 Julauthor updated this narrative How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.
CRL Charles River Laboratories International US$278.0611.3% undervalued intrinsic discount -0.07%7D 50.3%3M A US$313.61author fair value 12 Marauthor updated this narrative A Company Preparing for the Future: Charles River Laboratories
FBIO Fortress Biotech US$2.5363.0% undervalued intrinsic discount 0.2%7D -15.6%3M A US$6.83author fair value 18 Julauthor updated this narrative A little Prince. FBIO.
A176750 DuChemBIOLtd ₩6,070.0039.3% undervalued intrinsic discount -1.0%7D -3.5%3M A ₩10kauthor fair value 23 Julauthor updated this narrative DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
ZTS Zoetis US$71.4017.8% undervalued intrinsic discount -2.2%7D -9.3%3M A US$86.83author fair value 20 Julauthor updated this narrative Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?
A214150 CLASSYS ₩31,300.0051.8% undervalued intrinsic discount -2.3%7D -33.0%3M A ₩65kauthor fair value 20 Julauthor updated this narrative Why Calling Classys Korea's #2 Aesthetic Player Is a Massive Mispricing
ROIV Roivant Sciences US$39.80298.0% overvalued intrinsic discount -2.5%7D 26.6%3M A US$10author fair value 19 Julauthor updated this narrative overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
ZVRA Zevra Therapeutics US$11.6122.6% undervalued intrinsic discount -3.3%7D -10.0%3M A US$15author fair value 20 Julauthor updated this narrative Zevra Therapeutics: Galloping Through a Green Safari
INMD InMode US$14.3633.8% undervalued intrinsic discount -3.6%7D 7.2%3M A US$21.69author fair value 17 Junauthor updated this narrative A Clear Case of Mispricing.
AKBA Akebia Therapeutics US$0.9298.8% undervalued intrinsic discount -3.8%7D -14.4%3M A US$77.29author fair value 24 Junauthor updated this narrative Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
BBIO BridgeBio Pharma US$66.61166.4% overvalued intrinsic discount -8.0%7D 0.5%3M A US$25author fair value 19 Julauthor updated this narrative Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
A053030 BINEX ₩5,990.0073.5% undervalued intrinsic discount -8.8%7D -21.7%3M A ₩22.57kauthor fair value 20 Julauthor updated this narrative Binex pivot to a global bio-CDMO requires more than Biosecure Act tailwinds; it demands a total cultural evolution from its 2021 compliance

Watching

		FV & Narrative	Valuation	Growth	Analyst Target
CAPR Capricor Therapeutics 8.4%7D -68.0%3M	US$9.08 84.4% undervalued intrinsic discount	A US$58author fair value 12 Julauthor updated this narrative The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough	PB 2.1x	E 67.4%	US$27.00
MBIO Mustang Bio 2.9%7D -19.7%3M	US$0.52 71.0% undervalued intrinsic discount	A US$1.8author fair value 24 Junauthor updated this narrative A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???	PB 0.5x	S n/a	n/a
PRTC PureTech Health 2.7%7D -6.7%3M	UK£1.23 63.0% undervalued intrinsic discount	A UK£3.31author fair value 19 Julauthor updated this narrative An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.	PB 1.3x	E 20.9%	UK£3.31
TDOC Teladoc Health 2.3%7D -21.9%3M	US$6.30 58.0% undervalued intrinsic discount	A US$15author fair value 21 Julauthor updated this narrative Pandemic Relic or Cash-Flow Bargain?	PS 0.5x	E 35.4%	US$7.67
AMGN Amgen 2.2%7D 14.2%3M	US$385.65 7.1% overvalued intrinsic discount	A US$359.98author fair value 19 Julauthor updated this narrative A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.	PE 23.8x	E 7.5%	US$387.69
RARE Ultragenyx Pharmaceutical 1.5%7D -47.1%3M	US$14.51 44.2% undervalued intrinsic discount	A US$26author fair value 19 Julauthor updated this narrative burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.	PS 2x	E 75.3%	US$28.05
RCKT Rocket Pharmaceuticals 0.7%7D 0.7%3M	US$3.38 66.3% undervalued intrinsic discount	A US$10author fair value 24 Junauthor updated this narrative The Structural Disconnect Between Market Valuation and Operational Maturity	PB 1x	E -20.3%	US$8.85
CSBT.F Kuros Biosciences 0%7D n/a3M	US$24.00 93.0% undervalued intrinsic discount	A US$342.18author fair value 26 Julauthor updated this narrative How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.	PE 89x	E 58.6%	US$49.45
CRL Charles River Laboratories International -0.07%7D 50.3%3M	US$278.06 11.3% undervalued intrinsic discount	A US$313.61author fair value 12 Marauthor updated this narrative A Company Preparing for the Future: Charles River Laboratories	PS 3.3x	E 43.9%	US$282.43
FBIO Fortress Biotech 0.2%7D -15.6%3M	US$2.53 63.0% undervalued intrinsic discount	A US$6.83author fair value 18 Julauthor updated this narrative A little Prince. FBIO.	PE 0.8x	E -128.8%	US$11.00
A176750 DuChemBIOLtd -1.0%7D -3.5%3M	₩6,070.00 39.3% undervalued intrinsic discount	A ₩10kauthor fair value 23 Julauthor updated this narrative DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.	PE 25.2x	S n/a	n/a
ZTS Zoetis -2.2%7D -9.3%3M	US$71.40 17.8% undervalued intrinsic discount	A US$86.83author fair value 20 Julauthor updated this narrative Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?	PE 11.2x	E 3.5%	US$96.00
A214150 CLASSYS -2.3%7D -33.0%3M	₩31,300.00 51.8% undervalued intrinsic discount	A ₩65kauthor fair value 20 Julauthor updated this narrative Why Calling Classys Korea's #2 Aesthetic Player Is a Massive Mispricing	PE 14.8x	E 25.9%	₩63,000.00
ROIV Roivant Sciences -2.5%7D 26.6%3M	US$39.80 298.0% overvalued intrinsic discount	A US$10author fair value 19 Julauthor updated this narrative overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.	PB 6.8x	E 42.3%	US$47.79
ZVRA Zevra Therapeutics -3.3%7D -10.0%3M	US$11.61 22.6% undervalued intrinsic discount	A US$15author fair value 20 Julauthor updated this narrative Zevra Therapeutics: Galloping Through a Green Safari	PE 12x	E 24.3%	US$25.00
INMD InMode -3.6%7D 7.2%3M	US$14.36 33.8% undervalued intrinsic discount	A US$21.69author fair value 17 Junauthor updated this narrative A Clear Case of Mispricing.	PE 10.6x	E -0.03%	US$16.17
AKBA Akebia Therapeutics -3.8%7D -14.4%3M	US$0.92 98.8% undervalued intrinsic discount	A US$77.29author fair value 24 Junauthor updated this narrative Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio	PS 1.2x	E 20.5%	US$3.92
BBIO BridgeBio Pharma -8.0%7D 0.5%3M	US$66.61 166.4% overvalued intrinsic discount	A US$25author fair value 19 Julauthor updated this narrative Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins	PS 18.3x	E 68.9%	US$109.10
A053030 BINEX -8.8%7D -21.7%3M	₩5,990.00 73.5% undervalued intrinsic discount	A ₩22.57kauthor fair value 20 Julauthor updated this narrative Binex pivot to a global bio-CDMO requires more than Biosecure Act tailwinds; it demands a total cultural evolution from its 2021 compliance	PS 1.2x	S 16.0%	₩12,550.00

Bio Tech Plays. Mispricing

Watching

The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

Pandemic Relic or Cash-Flow Bargain?

A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.

burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.

The Structural Disconnect Between Market Valuation and Operational Maturity

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

A Company Preparing for the Future: Charles River Laboratories

A little Prince. FBIO.

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?

Why Calling Classys Korea's #2 Aesthetic Player Is a Massive Mispricing

overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.

Zevra Therapeutics: Galloping Through a Green Safari

A Clear Case of Mispricing.

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Binex pivot to a global bio-CDMO requires more than Biosecure Act tailwinds; it demands a total cultural evolution from its 2021 compliance

Watching

The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

Pandemic Relic or Cash-Flow Bargain?

A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.

burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.

The Structural Disconnect Between Market Valuation and Operational Maturity

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

A Company Preparing for the Future: Charles River Laboratories

A little Prince. FBIO.

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?

Why Calling Classys Korea's #2 Aesthetic Player Is a Massive Mispricing

overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.

Zevra Therapeutics: Galloping Through a Green Safari

A Clear Case of Mispricing.

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Binex pivot to a global bio-CDMO requires more than Biosecure Act tailwinds; it demands a total cultural evolution from its 2021 compliance

Comments